Currently, there are 261.64M common shares owned by the public and among those 251.86M shares have been available to trade.
The company’s stock has a 5-day price change of 13.64% and 80.56% over the past three months. AKBA shares are trading 71.05% year to date (YTD), with the 12-month market performance up to 215.53% higher. It has a 12-month low price of $0.80 and touched a high of $3.14 over the same period. AKBA has an average intraday trading volume of 4.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.13%, 41.83%, and 70.48% respectively.
Institutional ownership of Akebia Therapeutics Inc (NASDAQ: AKBA) shares accounts for 36.60% of the company’s 261.64M shares outstanding.
It has a market capitalization of $853.57M and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$0.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.76% over the week and 3.78% over the month.
Analysts forecast that Akebia Therapeutics Inc (AKBA) will achieve an EPS of -0.04 for the current quarter, -0.03 for the next quarter and 0.42 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.04 while analysts give the company a high EPS estimate of -0.04. Comparatively, EPS for the current quarter was -0.04 a year ago. Earnings per share for the fiscal year are expected to increase by 68.48%, and 117.31% over the next financial year.
Looking at the support for the AKBA, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on April 28, 2025, with the firm’s price target at $7. Jefferies coverage for the Akebia Therapeutics Inc (AKBA) stock in a research note released on April 01, 2025 offered a Buy rating with a price target of $6. BTIG Research was of a view on November 29, 2023 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on August 28, 2023, issuing a price target of $3.75. Piper Sandler on their part issued Overweight rating on May 31, 2023.
